Zobrazeno 1 - 10
of 5 326
pro vyhledávání: '"L. Ayres"'
Autor:
Menger, Karl
Publikováno v:
Transactions of the American Mathematical Society, 1931 Jul 01. 33(3), 663-667.
Externí odkaz:
https://www.jstor.org/stable/1989330
Autor:
Briggman, Anthony
Publikováno v:
Vigiliae Christianae, 2013 Jan 01. 67(5), 557-562.
Externí odkaz:
https://www.jstor.org/stable/42003529
Autor:
Grig, Lucy
Publikováno v:
The Journal of Hellenic Studies, 2005 Jan 01. 125, 169-170.
Externí odkaz:
https://www.jstor.org/stable/30033365
Autor:
Stanisław Longosz
Publikováno v:
Vox Patrum, Vol 46 (2004)
recenzja
Externí odkaz:
https://doaj.org/article/6ab01e4b2597448f931619896996a365
Autor:
Streeten, Paul
Publikováno v:
Journal of Economic Literature, 1984 Sep 01. 22(3), 1146-1149.
Externí odkaz:
https://www.jstor.org/stable/2725330
Autor:
Ascher, William
Publikováno v:
Policy Sciences, 1983 Nov 01. 16(2), 192-196.
Externí odkaz:
https://www.jstor.org/stable/4531981
Autor:
Natalia Timofeeva, Mary L. Ayres, Natalia Baran, Janice M. Santiago-O’Farrill, Gamze Bildik, Zhen Lu, Marina Konopleva, Varsha Gandhi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionChronic lymphocytic leukemia (CLL) cells are metabolically flexible and adapt to modern anticancer treatments. Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become
Externí odkaz:
https://doaj.org/article/5f4424f292934236ac1ccec24c8ba64a
Autor:
Anthony Briggman
Publikováno v:
Vigiliae Christianae. 67:557-562
Autor:
Hodge, W. V. D.
Publikováno v:
The Mathematical Gazette, 1942 May 01. 26(269), 113-115.
Externí odkaz:
https://www.jstor.org/stable/3605701
Autor:
Burcu Aslan, Gorkem Kismali, Lakesla R. Iles, Ganiraju C. Manyam, Mary L. Ayres, Lisa S. Chen, Mihai Gagea, Maria Teresa Sabrina Bertilaccio, William G. Wierda, Varsha Gandhi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-12 (2022)
Abstract Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pi
Externí odkaz:
https://doaj.org/article/8888c6f8f7de463288f684d22b1c67b9